Abstract:Background: LCL161, a novel Smac mimetic, is known to have anti-tumor activity and improve chemosensitivity in various cancers. However, the function and mechanisms of the combination of LCL161 and paclitaxel in non-small cell lung cancer (NSCLC) remain unknown. Methods: Cellular inhibitor of apoptotic protein 1 and 2 (cIAP1&2) expression in NSCLC tissues and adjacent non-tumor tissues were assessed by immunohistochemistry. The correlations between cIAP1&2 expression and clinicopathological characteristics, prognosis were analyzed. Cell viability and apoptosis were measured by MTT assays and Flow cytometry. Western blot and co-immunoprecipitation assay were performed to measure the protein expression and interaction in NF-kB pathway. siRNA-mediated gene silencing and caspases activity assays were applied to demonstrate the role and mechanisms of cIAP1&2 and RIP1 in lung cancer cell apoptosis. Mouse xenograft NSCLC models were used in vivo to determine the therapeutic efficacy of LCL161 alone or in combination with paclitaxel. Results: The expression of cIAP1 and cIAP2 in Non-small cell lung cancer (NSCLC) tumors was significantly higher than that in adjacent normal tissues. cIAP1 was highly expressed in patients with late TNM stage NSCLC and a poor prognosis. Positivity for both cIAP1 and cIAP2 was an independent prognostic factor that indicated a poorer prognosis in NSCLC patients. LCL161, an IAP inhibitor, cooperated with paclitaxel to reduce cell viability and induce apoptosis in NSCLC cells. Molecular studies revealed that paclitaxel increased TNFα expression, thereby leading to the recruitment of various factors and the formation of the TRADD-TRAF2-RIP1-cIAP complex. LCL161 degraded cIAP1&2 and released RIP1 from the complex. Subsequently, RIP1 was stabilized and bound to caspase-8 and FADD, thereby forming the caspase-8/RIP1/FADD complex, which activated caspase-8, caspase-3 and ultimately lead to apoptosis. In nude mouse xenograft experiments, the combination of LCL161 and paclitaxel degraded cIAP1,2, activated caspase-3 and inhibited tumor growth with few toxic effects. Conclusion: Thus, LCL161 could be a useful agent for the treatment of NSCLC in combination with paclitaxel.

Chemosensitization in Non-Small Cell Lung Cancer Cells by Ikk Inhibitor Occurs Via Nf-Kappa B and Mitochondrial Cytochrome C Cascade

Sesquiterpene Lactone Parthenolide Markedly Enhances Sensitivity of Human A549 Cells to Low-Dose Oxaliplatin Via Inhibition of NF-κB Activation and Induction of Apoptosis

Nuclear factor-κB inhibition by parthenolide potentiates the efficacy of taxol in non-small cell lung cancer in vitro and in vivo

Effects of Pennogenin 3-O-<i>β</i>-Chacotrioside, a Steroidal Saponin from <i>Rhizoma paridis</i>, on Proliferation Inhibition and Apoptosis Induction in Non-Small Cell Lung Cancer Cells

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction

Parthenolide Induces Proliferation Inhibition and Apoptosis of Pancreatic Cancer Cells in Vitro

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

The Novel Triazolonaphthalimide Derivative Lss-11 Synergizes The Anti-Proliferative Effect Of Paclitaxel Via Stat3-Dependent Mdr1 And Mrp1 Downregulation In Chemoresistant Lung Cancer Cells

Peneciraistin C Induces Caspase-Independent Autophagic Cell Death Through Mitochondrial-Derived Reactive Oxygen Species Production in Lung Cancer Cells

Chrysin-functionalized gold nanoparticles and paclitaxel exhibit synergistic impact on lung cancer cell lines via regulating the AKT/PPAR-ϒ/β-catenin pathway

Nuclear Factor-Kappab/ikappab Signaling Pathway May Contribute to the Mediation of Paclitaxel-Induced Apoptosis in Solid Tumor Cells.

Synergistic Effects of Apigenin and Paclitaxel on Apoptosis of Cancer Cells.

Parthenolide Inhibits Synthesis and Promotes Degradation of Programmed Cell Death Ligand 1 and Enhances T Cell Tumor-Killing Activity

P2.03a-059 LCL161 Increases Paclitaxel-Induced Apoptosis by Degrading Ciap1 and Ciap2 in NSCLC: Topic: Clinical Trials

Paclitaxel And Ceramide Synergistically Induce Cell Death With Transient Activation Of Egfr And Erk Pathway In Pancreatic Cancer Cells

Dasatinib Promotes Paclitaxel-Induced Necroptosis in Lung Adenocarcinoma with Phosphorylated Caspase-8 by C-Src

The Anticancer Efficacy of Paclitaxel Liposomes Modified with Mitochondrial Targeting Conjugate in Resistant Lung Cancer

LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC

Preconditioning Chemotherapy With Paclitaxel And Cisplatin Enhances The Antitumor Activity Of Cytokine Induced-Killer Cells In A Murine Lung Carcinoma Model

IκB Kinase Activation is Involved in Regulation of Paclitaxel-Induced Apoptosis in Human Tumor Cell Lines